Impact of systemic corticosteroids for cutaneous immune-related adverse events on survival outcomes in patients with advanced cancer: A retrospective cohort study.
Jaewon Yoon(Massachusetts General Hospital), Steven T. Chen(Hess (United States)), Michael S. Chang(Harvard University), Gabriel E. Molina(Harvard University), Kerry L. Reynolds(Massachusetts General Hospital), Nicole J. Polyakov(Harvard University), Kevin Huang(Harvard University), Devon E. McMahon(Harvard University), Juhi R. Kuchroo(Harvard University), Jordan T. Said(Harvard University), Andrea N. Hinton(Harvard University), Nira A. Krasnow(University of California, San Francisco), Leah L. Thompson(Massachusetts General Hospital), Edward Li(Sanden (Japan))
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589